Published in Cancer Res on September 15, 1990
Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut (1996) 1.22
Primary carcinoid tumour of the kidney: a review of the literature. Adv Urol (2013) 1.22
Regulatory peptide receptors in human hepatocellular carcinomas. Gut (1999) 1.22
Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol (1999) 1.15
Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut (1998) 1.09
Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting. J Med Chem (2008) 1.09
Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut (2002) 1.08
Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours. Eur J Nucl Med Mol Imaging (2008) 1.07
Immunohistochemical localization of somatostatin receptors sst2A in human tumors. Am J Pathol (1998) 1.04
Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting. Am J Surg Pathol (2012) 1.01
Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur J Nucl Med Mol Imaging (2003) 0.98
Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors. Nat Clin Pract Oncol (2009) 0.96
Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments. Clin Transl Imaging (2014) 0.95
PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms. Theranostics (2014) 0.95
The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide. Yale J Biol Med (1993) 0.94
Ectopic insulin secreting neuroendocrine tumor of kidney with recurrent hypoglycemia: a diagnostic dilemma. BMC Endocr Disord (2014) 0.93
SST3-selective potent peptidic somatostatin receptor antagonists. Proc Natl Acad Sci U S A (2000) 0.93
Novel, potent, and radio-iodinatable somatostatin receptor 1 (sst1) selective analogues. J Med Chem (2009) 0.91
Cholecystokinin-B/gastrin receptors enhance wound healing in the rat gastric mucosa. J Clin Invest (2000) 0.90
A new era for the systemic therapy of neuroendocrine tumors. Oncologist (2012) 0.89
Somatostatin receptors on neuroendocrine tumors--a way to intraoperative diagnosis and localization. Yale J Biol Med (1996) 0.89
Typical bronchial carcinoid metastasizing to the brain: a case presentation. Case Rep Oncol (2011) 0.88
Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT. Int J Mol Imaging (2011) 0.85
Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas. J Clin Pathol (2006) 0.84
The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors. Ann Surg (1996) 0.84
An enteric pathogen Salmonella enterica serovar Typhimurium suppresses tumor growth by downregulating CD44high and CD4T regulatory (Treg) cell expression in mice: the critical role of lipopolysaccharide and Braun lipoprotein in modulating tumor growth. Cancer Gene Ther (2009) 0.84
Cellular detection of sst2A receptors in human gastrointestinal tissue. Gut (2004) 0.83
Illuminating somatostatin analog action at neuroendocrine tumor receptors. Trends Pharmacol Sci (2013) 0.83
Concordance between results of somatostatin receptor scintigraphy with 111In-DOTA-DPhe 1-Tyr 3-octreotide and chromogranin A assay in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2008) 0.81
Preoperative localization of gastrointestinal endocrine tumors using somatostatin-receptor scintigraphy. Ann Surg (1993) 0.81
Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog. Eur J Nucl Med Mol Imaging (2010) 0.79
The pathobiology of the human enterochromaffin-like cell. Yale J Biol Med (1994) 0.79
Pituitary adenylate-cyclase-activating polypeptide (PACAP) binding sites and PACAP/vasoactive intestinal polypeptide receptor expression in human pituitary adenomas. Am J Pathol (1998) 0.78
Scintigraphic detection of carcinoid tumors with a cost effectiveness analysis. World J Gastroenterol (2004) 0.78
Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook. Mol Diagn Ther (2012) 0.78
Somatostatin receptors in differentiated ovarian tumors. Am J Pathol (1991) 0.77
New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors. Gastroenterol Clin North Am (2010) 0.76
Medical treatment for gastro-entero-pancreatic neuroendocrine tumours. World J Gastrointest Oncol (2016) 0.76
Somatostatin receptors in the gastrointestinal tract in health and disease. Yale J Biol Med (1993) 0.76
Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies. EJNMMI Res (2015) 0.75
Clinical utility of indigenously formulated single-vial lyophilized HYNIC-TOC kit in evaluating Gastro-entero Pancreatic neuro endocrine tumours. Asia Ocean J Nucl Med Biol (2014) 0.75
Role of bilateral inferior petrosal sinus sampling (BIPSS) in the diagnosis of Cushing's disease in a patient with double superior vena cava. J Radiol Case Rep (2015) 0.75
[111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study. EJNMMI Res (2012) 0.75
Somatostatin receptor staining in FFPE sections using a ligand derivative dye as an alternative to immunostaining. PLoS One (2017) 0.75
In liver metastases from small intestinal neuroendocrine tumors, SSTR2A expression is heterogeneous. Virchows Arch (2017) 0.75
Biliary tract cancers. N Engl J Med (1999) 6.36
Surgical management of intussusception in the adult. Ann Surg (1981) 5.42
Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res (1985) 4.39
Complications following pancreaticoduodenectomy. Current management. Arch Surg (1992) 3.94
Course of alcoholic chronic pancreatitis: a prospective clinicomorphological long-term study. Gastroenterology (1996) 3.81
Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation (1993) 3.29
Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med (2000) 3.26
Primary venous leiomyosarcoma: a rare but lethal disease. J Vasc Surg (1992) 3.05
Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer (1991) 2.98
Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann Surg (1992) 2.97
Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med (1986) 2.70
Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med (2001) 2.41
Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol (2000) 2.27
Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg (1997) 2.13
Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. N Engl J Med (1990) 2.12
What prognostic factors are important in duodenal adenocarcinoma? Arch Surg (2000) 2.03
Complications of percutaneous ethanol ablation. J Ultrasound Med (1998) 2.03
Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med (1987) 1.99
"Natural history" of unresected cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc (1995) 1.97
Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg (1999) 1.94
CT and sonographically guided needle biopsy: current techniques and new innovations. AJR Am J Roentgenol (1990) 1.93
CT- and US-guided biopsy of the pancreas. Radiology (1993) 1.93
Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch (1995) 1.91
Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg (1995) 1.82
Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood (1998) 1.79
Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg (1991) 1.78
Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging (2007) 1.72
Neuroendocrine ampullary tumors: spectrum of disease including the first report of a neuroendocrine carcinoma of non-small cell type. Surgery (1994) 1.72
Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/- 5 fluorouracil. Int J Radiat Oncol Biol Phys (1993) 1.71
Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med (1981) 1.70
Replacement of the inferior vena cava for malignancy: an update. J Vasc Surg (2000) 1.66
Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res (1997) 1.64
MEN1 gene mutation analysis of sporadic adrenocortical lesions. Int J Cancer (1999) 1.63
Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene (2003) 1.63
Spectrum and management of major complications of laparoscopic cholecystectomy. Am J Surg (1993) 1.59
Primary signet ring cell adenocarcinoma of the bladder. J Urol (1989) 1.55
Pancreatic endocrine tumors. Hum Pathol (1982) 1.55
Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists. J Med Chem (2002) 1.53
Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res (1994) 1.53
Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood (2000) 1.50
Radical resection for carcinoma of the ampulla of Vater. Arch Surg (1991) 1.49
Early gastric cancer. Br J Surg (1992) 1.49
Cholangiocarcinoma: diagnosis and evaluation of resectability by CT and sonography as procedures complementary to cholangiography. AJR Am J Roentgenol (1988) 1.48
Acute hypercalcemia induces acinar cell necrosis and intraductal protein precipitates in the pancreas of cats and guinea pigs. Gastroenterology (1990) 1.48
Resection of hepatocellular carcinoma in patients without cirrhosis. Br J Surg (2011) 1.48
The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy. Hepatology (1996) 1.48
Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery (1990) 1.47
A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N Engl J Med (1982) 1.47
Diagnosis of corticotropin-producing bronchial carcinoid tumors causing Cushing's syndrome. Mayo Clin Proc (1990) 1.46
Carcinoma of the gallbladder. Does radical resection improve outcome? Arch Surg (1990) 1.45
Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg (2001) 1.45
Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N Engl J Med (1993) 1.45
Distribution of the large aggregating proteoglycan versican in adult human tissues. J Histochem Cytochem (1996) 1.42
Pancreatic endocrine tumors. Pathol Res Pract (1988) 1.42
Trends in morbidity and mortality of hepatic resection for malignancy. A matched comparative analysis. Ann Surg (1994) 1.42
Immunohistochemical localisation of urogastrone to human duodenal and submandibular glands. Gut (1978) 1.41
Abnormal gallbladder motility in irritable bowel syndrome: evidence for target-organ defect. Am J Physiol (1991) 1.41
The role of portosystemic shunts for variceal bleeding in the liver transplantation era. Arch Surg (1994) 1.40
Suppressive therapy with levothyroxine for solitary thyroid nodules. A double-blind controlled clinical study. N Engl J Med (1987) 1.39
Pancreatic acinar cell carcinoma. An analysis of cell lineage markers, p53 expression, and Ki-ras mutation. Am J Pathol (1993) 1.39
CEA monitoring among patients in multi-institutional adjuvant G.I. therapy protocols. Ann Surg (1982) 1.38
Senile dementia of Alzheimer type: astroglial reaction to extracellular neurofibrillary tangles in the hippocampus. An immunocytochemical and electron-microscopic study. Acta Neuropathol (1982) 1.38
Choledochal cysts in adults: clinical management. Surgery (1984) 1.37
Benign pancreatic insulinoma: preoperative and intraoperative sonographic localization. AJR Am J Roentgenol (1986) 1.37
Determination of deltoid fat pad thickness. Implications for needle length in adult immunization. JAMA (1997) 1.36
Liver resection and cyst fenestration in the treatment of severe polycystic liver disease. Gastroenterology (1995) 1.36
Cystic pancreatic tumors: CT and sonographic assessment. AJR Am J Roentgenol (1988) 1.36
Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg (1990) 1.34
The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine (Baltimore) (1996) 1.33
Focal nodular hyperplasia and hepatic adenoma: comparison of angiography, CT, US, and scintigraphy. Radiology (1985) 1.31
Jejunogastric intussusception. Arch Surg (1980) 1.31
Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res (2000) 1.29
Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma. Arch Surg (2001) 1.29
Reexpression of poly(sialic acid) units of the neural cell adhesion molecule in Wilms tumor. Proc Natl Acad Sci U S A (1988) 1.28
Imaging-guided radiofrequency ablation of solid renal tumors. AJR Am J Roentgenol (2003) 1.27
Immunocytochemical markers of uncommon pancreatic tumors. Acinar cell carcinoma, pancreatoblastoma, and solid cystic (papillary-cystic) tumor. Cancer (1987) 1.27
Paranephric water instillation: a technique to prevent bowel injury during percutaneous renal radiofrequency ablation. AJR Am J Roentgenol (2003) 1.27
Duodenal carcinoid tumors: how aggressive should we be? J Gastrointest Surg (2002) 1.26
Small cell neuroendocrine (oat cell) carcinoma of the male breast. Immunocytochemical and ultrastructural investigations. Virchows Arch A Pathol Anat Histopathol (1984) 1.26
Pathology and nomenclature of human gastrointestinal neuroendocrine (carcinoid) tumors and related lesions. World J Surg (1996) 1.26
Outcome of cardiac surgery for carcinoid heart disease. J Am Coll Cardiol (1995) 1.25
Surgical management of intrahepatic cholangiocarcinoma: a 31-year experience. J Hepatobiliary Pancreat Surg (1998) 1.24
Diffuse and focal nesidioblastosis. A clinicopathological study of 24 patients with persistent neonatal hyperinsulinemic hypoglycemia. Am J Surg Pathol (1989) 1.24
Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut (1996) 1.22
The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med (1994) 1.22
Regulatory peptide receptors in human hepatocellular carcinomas. Gut (1999) 1.22
Long-term results of biliary reconstruction after laparoscopic bile duct injuries. Arch Surg (1999) 1.21
Preoperative detection of pancreatic insulinomas on multiphasic helical CT. AJR Am J Roentgenol (2003) 1.20
Treatment of highly symptomatic polycystic liver disease. Preliminary experience with a combined hepatic resection-fenestration procedure. Ann Surg (1990) 1.18
Sigmoid diverticulitis with perforation and generalized peritonitis. Dis Colon Rectum (1985) 1.17
Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization. Am J Pathol (1999) 1.16
Expression of alpha 2,6-linked sialic acid residues in neoplastic but not in normal human colonic mucosa. A lectin-gold cytochemical study with Sambucus nigra and Maackia amurensis lectins. Am J Pathol (1991) 1.16